Sareum Holdings plc (LON:SAR – Get Free Report) dropped 8.9% on Wednesday . The stock traded as low as GBX 28 ($0.37) and last traded at GBX 28.24 ($0.37). Approximately 439,010 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 721,062 shares. The stock had previously closed at GBX 31 ($0.40).
Sareum Stock Down 3.6 %
The firm has a market cap of £29.15 million, a price-to-earnings ratio of -450.00 and a beta of -1.08. The business has a 50 day moving average price of GBX 28.11 and a 200-day moving average price of GBX 29.95.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Featured Stories
- Five stocks we like better than Sareum
- What is a Special Dividend?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Quiet Period Expirations Explained
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Using the MarketBeat Stock Split Calculator
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
